Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson’s disease models

Current treatments for Parkinson’s disease (PD) provide only symptomatic relief, with no disease-modifying therapies identified to date. Repurposing FDA-approved drugs to treat PD could significantly shorten the time needed for and reduce the costs of drug development compared with conventional appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Burbulla, Lena F., Zheng, Jianbin, Song, Pingping, Jiang, Weilan, Johnson, Michaela E., Brundin, Patrik, Krainc, Dimitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525588/
https://www.ncbi.nlm.nih.gov/pubmed/34622801
http://dx.doi.org/10.1172/jci.insight.148649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525588/
https://www.ncbi.nlm.nih.gov/pubmed/34622801
http://dx.doi.org/10.1172/jci.insight.148649

Ejemplares similares